Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis

Phase 2 Active not recruiting 40 enrolled University of California, Irvine

NaSingle-groupOpen-labelTreatment

Summary

This is a phase II clinical trial assessing the safety and efficacy of sequential systemic and intraperitoneal (IP) chemotherapy in patients with primary gastric/gastroesophageal junction cancer with cytology positive peritoneal lavage and/or peritoneal carcinomatosis.

Timeline

Start: 2021-02-18
Primary completion: 2026-12
Completion: 2026-12

Publications

Senthil M, Dayyani F. Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial. BMC Cancer. 2023 Mar 4;23(1):209. doi: 10.1186/s12885-023-10680-1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Leucovorin	Small molecule	—	Intravenous
Subject	Paclitaxel	Small molecule	40 mg/m2	Intravenous
Subject	fluorouracil	Small molecule	—	Intravenous

Study of Sequential Systemic Therapy + Intraperitoneal Paclitaxel in Gastric/GEJ Peritoneal Carcinomatosis

Summary

Timeline

Publications

Drugs

Indications